Spero Therapeutics (SPRO) Free Cash Flow Growth (1y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 60.84% |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 88.70% |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -15.72% |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 66.37% |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 3.98% |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 137.65% |
| 10 | Spero Therapeutics | 154.37 Mn | 98.24 Mn | - | 496.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 496.40% |
| Dec 31, 2025 | 64.31% |
| Sep 30, 2025 | 36.50% |
| Jun 30, 2025 | 5.61% |
| Mar 31, 2025 | -167.40% |
| Dec 31, 2024 | -33.77% |
| Sep 30, 2024 | -19.81% |
| Jun 30, 2024 | -0.97% |
| Mar 31, 2024 | 146.20% |
| Dec 31, 2023 | -139.33% |
| Sep 30, 2023 | 1,763.01% |
| Jun 30, 2023 | 19.40% |
| Mar 31, 2023 | 54.46% |
| Dec 31, 2022 | 262.88% |
| Sep 30, 2022 | 80.67% |
| Jun 30, 2022 | -39.03% |
| Mar 31, 2022 | -82.33% |
| Dec 31, 2021 | -66.58% |
| Sep 30, 2021 | 76.77% |
| Jun 30, 2021 | 33.50% |
| Mar 31, 2021 | 33.87% |
| Dec 31, 2020 | 6.29% |
| Sep 30, 2020 | -120.29% |
| Jun 30, 2020 | -104.91% |
| Mar 31, 2020 | -112.70% |
| Dec 31, 2019 | -29.21% |
| Sep 30, 2019 | -75.48% |
| Jun 30, 2019 | -40.69% |
| Mar 31, 2019 | 7.99% |
| Dec 31, 2018 | -6.30% |
| Sep 30, 2018 | 47.56% |
| Jun 30, 2018 | 2.66% |
| Mar 31, 2018 | -71.39% |
| Dec 31, 2017 | -34.59% |